Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

By Erwei Song, Pengcheng Zhu, Sang-Kyung Lee, Dipanjan Chowdhury, S. Kussman, D. Dykxhoorn, Yi Feng, D. Palliser, D. Weiner, P. Shankar and 2 more. Nature Biotechnology, 2005

1,045 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6d58b418ae20cca6e11dadd6851af3f2673d25a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. L. Aagaard
2. Daniel G. Anderson
3. M. Manoharan
4. Robert Langer
5. John J. Rossi

In Immunology

1. Robert Langer
2. John J. Rossi
3. Matthias Nahrendorf

In Molecular Biology

1. Robert Langer
2. John J. Rossi
3. Daniel G. Anderson
4. M. Manoharan
5. L. Aagaard
6. J. Lieberman
7. P. Murphy
8. Leigh-Ann MacFarlane

Citations in the corpus

• Strategies for silencing human disease using RNA interference (2007, neutral): “Heavy-chain antibody fragments (Fabs) that are specific for the HIV-1 envelope glycoprotein gp120 have been used to achieve selective delivery of siRNAs to HIV-infected cells both in culture and in vivo”
• Interfering with disease: a progress report on siRNA-based therapeutics (2007, background): “A protamine-antibody fusion protein delivered non-covalently bound siRNA to HIV-envelope-expressing B16 melanoma cells or HIV-infected primary CD4 T cells in vitro with high efficiency 101 .”
• Breaking down the barriers: siRNA delivery and endosome escape (2010, background): “…et al., 2005), lipids and liposomes (Akinc et al., 2008; Wu and McMillan, 2009), antibody (Ab)-fusion molecules [Ab-protamine (Peer et al., 2007; Song et al., 2005) and Ab-poly-arginine (Kumar et al., 2008)], as well as cholesterol- (Soutschek et al., 2004; Zimmermann et al., 2006) and…”
• MicroRNA: Biogenesis, Function and Role in Cancer (2010, background): “Progress is also being made in the expanding field of nanobiotechnology to develop a means to package and deliver RNA to specific sites [377-380].”
• Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery (2012, background): “It is hypothesized that intracellular delivery of the ONPs will be promoted by active targeting of specific surface receptors on cancer cells 20,21 .”
• siRNA delivery systems for cancer treatment. (2009, methodology): “Protamine-antibody fusion protein was used for antibodymediated targeted delivery of siRNA to melanoma cells expressing HIV envelope glycoprotein gp160 [89].”
• A combinatorial library of lipid-like materials for delivery of RNAi therapeutics (2008, background): “and, more recently, complexation with antibody fusion protein”